Pii to Manufacture FDA-Approved Breast Cancer Drug
Pii is now responsible for commercial drug product production of fulvestrant, a breast cancer drug, while Sagent Pharmaceuticals, its abbreviated new drug application holder, will sell, market, and distribute the drug product in the United States.
Pharmaceutics International, Inc. (Pii), a Hunt Valley, MD-based contract development and manufacturing organization, announced that FDA has approved its commercial supply of fulvestrant injection 250mg/5ml drug product for the treatment of breast cancer in post-menopausal patients. Pii is now responsible for commercial drug product production while Sagent Pharmaceuticals, who holds the drug’s abbreviated new drug application, will sell, market, and distribute the drug product in the United States.
“We are pleased to support Sagent Pharmaceuticals in its efforts to supply an affordable treatment option for post-menopausal patients suffering from breast cancer,” said Dr. Kurt Nielsen, Pii's president and CEO, in a Sept. 23, 2019 press release. “Pii’s Pharmaceutics Know-How has once again proven valuable to one of our partners, as they strive to develop and provide approved drug products to patients in need. Fulvestrant [i]njection 250mg/5ml drug product is the [fifth] injectable product approved and produced by Pii, during the past two years.”
Fulvestrant is the generic version of AstraZeneca’s Faslodex (fulvestrant), approved by FDA in 2002.
Source: Pii
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
